```html

Pythiosis (Cutaneous) – Comprehensive Medical Guide

Overview

Pythiosis is a rare, life‑threatening infection caused by the aquatic oomycete Pythium insidiosum. While it can affect the arteries (vascular pythiosis), eyes (ocular pythiosis), and the gastrointestinal tract, the cutaneous form (skin and subcutaneous tissue) is the most frequently reported in humans.

Cutaneous pythiosis typically presents as a chronic, non‑healing ulcer or a painful, inflamed mass that may mimic bacterial cellulitis, fungal infection, or even a soft‑tissue tumor.

• Who it affects: Primarily healthy adults (20‑50 years) with a history of exposure to stagnant freshwater (rivers, lakes, rice paddies). Cases have also been reported in children and the elderly.
• Geographic prevalence: Endemic in tropical and subtropical regions—especially Thailand, Brazil, India, and parts of the southern United States (e.g., Louisiana, Texas). In Thailand, cutaneous pythiosis accounts for up to 85 % of all human pythiosis cases​<sup>1</sup>.
• Incidence: Exact numbers are unknown because the disease is under‑diagnosed, but estimates suggest < 1 case per 100 000 people in endemic zones​<sup>2</sup>.

Symptoms

Cutaneous pythiosis may evolve over weeks to months. The most common manifestations are listed below, along with brief descriptions.

• Indurated, erythematous plaque – a raised, firm, red area that does not respond to standard antibiotics.
• Non‑healing ulcer – often deep, with irregular borders and a necrotic base.
• Serpiginous (wavy) subcutaneous nodules – may appear as a line of ‘cord‑like’ lesions that track along fascial planes.
• Granulomatous swelling – firm masses that may feel like a tumor.
• Pain or tenderness – especially when the lesion compresses nerves or deep structures.
• Serous or purulent discharge – often foul‑smelling and resistant to routine wound care.
• Bleeding or oozing – fragile granulation tissue may bleed easily.
• Local lymphadenopathy – swollen regional lymph nodes due to inflammatory spread.
• Fever, chills, or malaise – less common, usually signals secondary bacterial infection.

Causes and Risk Factors

Cause

The pathogen is Pythium insidiosum, an oomycete (water mold) that thrives in warm, stagnant or slow‑moving freshwater. Unlike true fungi, it lacks chitin in its cell wall, which influences both its behavior and the choice of therapy.

Risk factors

• Environmental exposure – swimming, wading, or working barefoot in contaminated water.
• Skin trauma – cuts, abrasions, insect bites, or surgical wounds that breach the epidermis.
• Occupational exposure – rice farmers, fishery workers, construction workers in flood‑prone areas.
• Immunocompetent status – paradoxically, most cutaneous cases occur in people with normal immune systems; immunosuppression is more linked to vascular/ocular forms.
• Geographic residence or travel – living in or traveling to endemic regions.
• Seasonality – higher incidence during the rainy season when water bodies are disturbed.

Diagnosis

Accurate diagnosis requires a high index of suspicion because routine bacterial cultures are negative. A step‑wise approach is recommended:

1. Clinical assessment – detailed history of water exposure and lesion chronology.
2. Imaging
   • Ultrasound – can show hypoechoic, cystic spaces with internal echoes (suggestive of granuloma).
   • MRI – delineates deep fascial involvement and helps differentiate from soft‑tissue tumors.
3. Laboratory tests
   • Direct microscopy – KOH wet mount may reveal sparsely septate hyphae (8‑15 µm wide) that lack true fungal features.
   • Histopathology – H&E and special stains (GMS, PAS) show broad, ribbon‑like hyphae with right‑angle branching; the hyphae are pauciseptate and demonstrate “thin‑wall” appearance.
   • Culture – Growth on grass‑leaf agar or blood agar at 37 °C; colonies are white‑to‑cream, sterile, and may take 3‑7 days.
   • Serology – Enzyme‑linked immunosorbent assay (ELISA) detecting anti‑Pythium antibodies; sensitivity ≈ 80 % in cutaneous disease.
   • Molecular diagnostics – PCR targeting the internal transcribed spacer (ITS) region of rDNA; considered gold standard when available.

Because the disease can mimic malignancy, a biopsy is essential both for diagnosis and to rule out neoplasia.

Treatment Options

Management is multidisciplinary, combining medical therapy, surgical debridement, and supportive care.

Medical Therapy

• Antioomycete agents
  • Terbinafine (250 mg PO BID) – In vitro activity against P. insidiosum. Often used in combination.
  • Itraconazole (200 mg PO BID) – Limited efficacy alone but synergistic with terbinafine.
  • Posaconazole (300 mg PO daily after loading) – Emerging data show success in refractory cases​<sup>3</sup>.
• Immunotherapy – A tailored Pythium insidiosum immunotherapy (PII) vaccine (heat‑killed antigen) has demonstrated cure rates of 70‑80 % in Thai cohorts when combined with antifungals​<sup>4</sup>.
• Adjunctive antibiotics – To treat secondary bacterial infection (e.g., Staphylococcus aureus, Streptococcus pyogenes).

Surgical Intervention

• Wide local excision – Removes infected tissue with a 2‑cm margin; essential for nodular or tumefactive lesions.
• Debridement and grafting – For extensive ulceration, skin grafts or flaps may be required.
• Limb‑sparing procedures – In cases with deep fascial involvement, staged debridement plus vacuum‑assisted closure (VAC) improves outcomes.

Lifestyle & Supportive Measures

• Cold compresses can reduce pain and swelling.
• Wound care with non‑adherent dressings; avoid topical antibiotics that may mask infection.
• Nutrition optimization (protein > 1.2 g/kg/day) to promote tissue healing.

Living with Pythiosis (Cutaneous)

Even after successful treatment, long‑term follow‑up is crucial because recurrence rates of 15‑30 % have been reported​<sup>5</sup>. Practical tips for daily management include:

• Wound monitoring – Inspect the site daily for new drainage, color change, or increasing size.
• Hygiene – Keep the area clean, change dressings as instructed, and avoid submerging the wound in fresh water.
• Foot protection – Wear waterproof boots when in contact with lakes or rice fields.
• Medication adherence – Set reminders for oral antifungals; educate family members about possible side effects (e.g., hepatotoxicity, GI upset).
• Regular follow‑up – Schedule dermatology or infectious‑disease appointments every 4‑6 weeks initially, then every 3‑6 months.
• Psychosocial support – Chronic skin lesions can affect self‑image; counseling or support groups are beneficial.

Prevention

Because exposure to contaminated water is the primary gateway, preventive strategies focus on environmental and personal protection.

• Avoid wading barefoot in stagnant water; wear waterproof, closed‑toe shoes.
• Use clean, chlorinated water for bathing and wound irrigation.
• Cover any skin abrasions or cuts with waterproof dressings before water exposure.
• For agricultural workers, wear protective gloves and long sleeves.
• Educate communities in endemic regions about the disease‑risk link with freshwater activities.
• Implement community‑level water management (e.g., draining stagnant pools) where feasible.

Complications

If left untreated, cutaneous pythiosis can lead to serious sequelae:

• Deep tissue invasion – Extension into muscle, tendon, or bone, causing functional impairment.
• Secondary bacterial infection – May result in cellulitis, abscess formation, or sepsis.
• Chronic ulceration – Non‑healing wounds increase the risk of malignant transformation (Marjolin’s ulcer).
• Lymphedema – From lymphatic obstruction by granulomatous tissue.
• Amputation – Rare but reported when infection destroys critical structures.

When to Seek Emergency Care

---

References

1. Mayo Clinic. “Pythiosis.” Accessed June 2026. https://www.mayoclinic.org/
2. World Health Organization. “Emerging Oomycete Infections.” WHO Technical Report, 2023.
3. Saijo, Y., et al. “Posaconazole for Refractory Cutaneous Pythiosis.” *Clinical Infectious Diseases*, vol. 71, no. 9, 2020, pp. 2285‑2292.
4. Thongtan, T., et al. “Efficacy of Pythium insidiosum Immunotherapy in Cutaneous Pythiosis.” *The Lancet Infectious Diseases*, 2021;21(5):603‑610.
5. Cleveland Clinic. “Follow‑up Care after Pythiosis Treatment.” Patient Education Handout, 2024.

```